Table 2.
Clinical description | Group | Number of patients (%) | Total |
---|---|---|---|
Follow-up time | 60–120 days | 7 (21.2%) | 33 |
≥120 days | 26(78.8%) | ||
CMV antigenemia | Positive* | 23 (69.7%) | 33 |
Negative** | 10 (30.3%) | ||
CMV disease | Yes | 2 (6.1%) | 33 |
No | 31 (93.9%) | ||
Acute GVHD | Grade 0 or I | 10 (45.5%) | 22 |
Grade II to IV | 12 (54.5%) | ||
Outcome | Alive at day 120 | 32 (97.0%) | 33 |
Death due to CMV disease | none | ||
Death due to other causes at day 120 | 1 (3.0%) |
CMV: cytomegalovirus; GVHD: Graft-versus-host disease.
At least one positive CMV antigenemia assay during the first 120 days of follow-up.
No positive antigenemia detected during the first 120 days of follow-up.